You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Litigation Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D.N.J. 2021)

✉ Email this page to a colleague

« Back to Dashboard

AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D.N.J. 2021)

Docket	⤷ Sign Up	Date Filed	2021-06-22
Court	District Court, D. New Jersey	Date Terminated	2021-09-10
Cause		Assigned To	Michael Andre Shipp
Jury Demand		Referred To	Douglas Arpert
Patents	10,039,745; 10,154,987; 6,028,222; 6,977,257; 8,568,747; 8,778,366; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553
Link to Docket	External link to docket

Small Molecule Drugs cited in AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D.N.J. 2021)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-08-23	29		-1067, which relates to asserted U.S. Patent No. 10,154,987, should also be included herein with …Judge Stark's Revised Procedures fo r Managing Patent Cases (which is posted at 1 …www.ded.uscourts.gov; see Chambers, Judge Leonard P. Stark, Patent Cases), and the parties having determined…Identification of Accused Product(s) and Asserted Patent(s). By December… and the asserted patent(s) they alleged infringe, and produce the	External link to document
2021-08-27	45	Reply Brief to Opposition to Motion	Shrestha Decl. Ex. M) ’745 patent U.S. Patent No. 10,039,745 B2 (ECF No. 9-5, 7/13/21… Decl. Ex. C) ’023 patent or patent-in-suit U.S. Patent No. 11,040,023 B2 (ECF No. 1-1,…PTO or Patent Office United States Patent and Trademark Office Second Wave Patents …the ’023 patent is “patentably indistinct” from the claims of the First and Second Wave Patents, which… ’023 patent are patentably indistinct from the claims of the First and Second Wave Patents, which	External link to document
2021-08-27	46		of U.S. Patent Nos. 9,669,008 (“the ’008 patent”); 9,808,442 (“the ’442 patent”); 10,039,745 (“the ’… ’745 patent”); and 10,154,987 (“the ’987 patent”) (collectively, “patents-in-suit”). Bionpharma has…II. The Patents-in-Suit. A. The ’008 Patent. The ‘008 patent, entitled …assignee on the face of the patent. The patent issued with 20 claims. ’008 patent at cover. …assignee on the face of the patent. The patent issued with 30 claims. ’442 patent at cover. The	External link to document
2021-10-01	60	Redacted Document	10,154,987 ’745 Patent U.S. Patent No. 10,039,745 ’868 Patent U.S. Patent No. 10,772,868…ABBREVIATIONS ’023 Patent U.S. Patent No. 11,040,023 ’008 Patent U.S. Patent No. 9,669,…9,669,008 ’442 Patent U.S. Patent No. 9,808,442 ’987 Patent U.S. Patent No. 10,154,987…10,772,868 ’482 Patent U.S. Patent No. 10,786,482 ’621 Patent U.S. Patent No. 10,918,621…to U.S. Patent Application No. 15/081,603 (now U.S. Patent No. 9,669,008, or “the ’008 Patent”). D.I	External link to document
2021-10-01	63	Redacted Document	’745 Patent U.S. Patent No. 10,039,745 ’868 Patent U.S. Patent No. 10,772,868 ’482 Patent…ABBREVIATIONS ’023 Patent U.S. Patent No. 11,040,023 (D.I. 1-1) ’008 Patent U.S. Patent No. 9,669,008…9,669,008 ’442 Patent U.S. Patent No. 9,808,442 ’987 Patent U.S. Patent No. 10,154,987 … Patent U.S. Patent No. 10,786,482 ’621 Patent U.S. Patent No. 10,918,621 ACE … infringes the ’023 Patent. Instead, Bionpharma contends that the ’023 patent (which is presumed valid	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.